Compare PVH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | CRNX |
|---|---|---|
| Founded | 1881 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | PVH | CRNX |
|---|---|---|
| Price | $66.14 | $33.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $89.27 | $74.78 |
| AVG Volume (30 Days) | 808.9K | ★ 1.0M |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $8,652,900,000.00 | $1,039,000.00 |
| Revenue This Year | $3.66 | $722.66 |
| Revenue Next Year | $1.79 | $183.79 |
| P/E Ratio | $17.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $59.28 | $24.10 |
| 52 Week High | $89.79 | $57.99 |
| Indicator | PVH | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 29.20 |
| Support Level | $60.58 | $33.23 |
| Resistance Level | $71.32 | $37.23 |
| Average True Range (ATR) | 2.08 | 1.62 |
| MACD | 0.49 | 0.13 |
| Stochastic Oscillator | 71.50 | 8.33 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, about 1,400 stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.